메뉴 건너뛰기




Volumn 111, Issue 10, 2014, Pages 1888-1898

HER2-positive advanced breast cancer: Optimizing patient outcomes and opportunities for drug development

Author keywords

breast neoplasm; Erbb 2; lapatinib; pertuzumab; trastuzumab; trastuzumab DM1

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HEAT SHOCK PROTEIN 90 INHIBITOR; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN KINASE B INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; TRASTUZUMAB; ERBB2 PROTEIN, HUMAN;

EID: 84917698578     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2014.388     Document Type: Review
Times cited : (99)

References (53)
  • 8
    • 34548178720 scopus 로고    scopus 로고
    • Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: The trastuzumab and vinorelbine or taxane study
    • Burstein HJ, Keshaviah A, Baron AD, Hart RD, Lambert-Falls R, Marcom PK, Gelman R, Winer EP (2007) Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study. Cancer 110(5): 965-972
    • (2007) Cancer , vol.110 , Issue.5 , pp. 965-972
    • Burstein, H.J.1    Keshaviah, A.2    Baron, A.D.3    Hart, R.D.4    Lambert-Falls, R.5    Marcom, P.K.6    Gelman, R.7    Winer, E.P.8
  • 11
    • 0023710206 scopus 로고
    • Comparing the areas under two or more correlated receiver operating characteristic curves: A nonparametric approach
    • DeLong ER, DeLong DM, Clarke-Pearson DL (1988) Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 44(3): 837-845
    • (1988) Biometrics , vol.44 , Issue.3 , pp. 837-845
    • Delong, E.R.1    Delong, D.M.2    Clarke-Pearson, D.L.3
  • 12
    • 2942623615 scopus 로고    scopus 로고
    • Monoclonal antibodies, small molecules, and vaccines in the treatment of breast cancer
    • Esteva FJ (2004) Monoclonal antibodies, small molecules, and vaccines in the treatment of breast cancer. Oncologist 9: 4-9
    • (2004) Oncologist , vol.9 , pp. 4-9
    • Esteva, F.J.1
  • 13
    • 77957352037 scopus 로고    scopus 로고
    • PTEN PIK3CA p-AKT, and p-p70S6K status: Association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer
    • Esteva FJ, Guo H, Zhang S, Santa-Maria C, Stone S, Lanchbury JS, Sahin AA, Hortobagyi GN, Yu D (2010) PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer. Am J Pathol 177(4): 1647-1656
    • (2010) Am J Pathol , vol.177 , Issue.4 , pp. 1647-1656
    • Esteva, F.J.1    Guo, H.2    Zhang, S.3    Santa-Maria, C.4    Stone, S.5    Lanchbury, J.S.6    Sahin, A.A.7    Hortobagyi, G.N.8    Yu, D.9
  • 19
    • 84901397460 scopus 로고    scopus 로고
    • Evaluation of everolimus (EVE) in HER2+ advanced breast cancer (BC) with activated PI3K/mTOR pathway: Exploratory biomarker observations from the BOLERO-3 trial
    • Jerusalem G, Andre F, Chen D, Robinson D, Ozguroglu M, Lang I, White M, Toi M, Taran T, Gianni L (2013) Evaluation of everolimus (EVE) in HER2+ advanced breast cancer (BC) with activated PI3K/mTOR pathway: exploratory biomarker observations from the BOLERO-3 trial. Eur J Cancer 49(Suppl 3): PS8
    • (2013) Eur J Cancer , vol.49 , Issue.SUPPL3 , pp. PS8
    • Jerusalem, G.1    Andre, F.2    Chen, D.3    Robinson, D.4    Ozguroglu, M.5    Lang, I.6    White, M.7    Toi, M.8    Taran, T.9    Gianni, L.10
  • 20
    • 84900434047 scopus 로고    scopus 로고
    • Pertuzumab in the treatment of HER2' breast cancer
    • Jhaveri K, Esteva FJ (2014) Pertuzumab in the treatment of HER2' breast cancer. J Natl Compr Canc Netw 12(4): 591-598
    • (2014) J Natl Compr Canc Netw , vol.12 , Issue.4 , pp. 591-598
    • Jhaveri, K.1    Esteva, F.J.2
  • 23
    • 73949105921 scopus 로고    scopus 로고
    • Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: Results from the randomized phase III TAnDEM study
    • Kaufman B, Mackey JR, Clemens MR, Bapsy PP, Vaid A, Wardley A, Tjulandin S, Jahn M, Lehle M, Feyereislova A, Revil C, Jones A (2009) Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study. J Clin Oncol 27(33): 5529-5537
    • (2009) J Clin Oncol , vol.27 , Issue.33 , pp. 5529-5537
    • Kaufman, B.1    Mackey, J.R.2    Clemens, M.R.3    Bapsy, P.P.4    Vaid, A.5    Wardley, A.6    Tjulandin, S.7    Jahn, M.8    Lehle, M.9    Feyereislova, A.10    Revil, C.11    Jones, A.12
  • 24
    • 0022406444 scopus 로고
    • Amplification of a novel v-erbB-related gene in a human mammary carcinoma
    • King CR, Kraus MH, Aaronson SA (1985) Amplification of a novel v-erbB-related gene in a human mammary carcinoma. Science 229(4717): 974-976
    • (1985) Science , vol.229 , Issue.4717 , pp. 974-976
    • King, C.R.1    Kraus, M.H.2    Aaronson, S.A.3
  • 25
    • 84863688392 scopus 로고    scopus 로고
    • A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine
    • Krop IE, LoRusso P, Miller KD, Modi S, Yardley D, Rodriguez G, Guardino E, Lu M, Zheng M, Girish S, Amler L, Winer EP, Rugo HS (2012) A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine. J Clin Oncol 30(26): 3234-3241
    • (2012) J Clin Oncol , vol.30 , Issue.26 , pp. 3234-3241
    • Krop, I.E.1    Lorusso, P.2    Miller, K.D.3    Modi, S.4    Yardley, D.5    Rodriguez, G.6    Guardino, E.7    Lu, M.8    Zheng, M.9    Girish, S.10    Amler, L.11    Winer, E.P.12    Rugo, H.S.13
  • 28
    • 84875722651 scopus 로고    scopus 로고
    • Prognostic and predictive value of tumour-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98
    • Loi S, Sirtaine N, Piette F, Salgado R, Viale G, Van Eenoo F, Rouas G, Francis P, Crown JP, Hitre E, De Azambuja E, Quinaux E, Di Leo A, Michiels S, Piccart MJ, Sotiriou C (2013) Prognostic and predictive value of tumour-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J Clin Oncol 31(7): 860-867
    • (2013) J Clin Oncol , vol.31 , Issue.7 , pp. 860-867
    • Loi, S.1    Sirtaine, N.2    Piette, F.3    Salgado, R.4    Viale, G.5    Van Eenoo, F.6    Rouas, G.7    Francis, P.8    Crown, J.P.9    Hitre, E.10    De Azambuja, E.11    Quinaux, E.12    Di Leo, A.13    Michiels, S.14    Piccart, M.J.15    Sotiriou, C.16
  • 30
  • 34
    • 1942474587 scopus 로고    scopus 로고
    • The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells
    • Nahta R, Hung MC, Esteva FJ (2004) The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. Cancer Res 64(7): 2343-2346
    • (2004) Cancer Res , vol.64 , Issue.7 , pp. 2343-2346
    • Nahta, R.1    Hung, M.C.2    Esteva, F.J.3
  • 35
    • 33646712747 scopus 로고    scopus 로고
    • Mechanisms of disease: Understanding resistance to HER2-targeted therapy in human breast cancer
    • Nahta R, Yu D, Hung MC, Hortobagyi GN, Esteva FJ (2006) Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nat Clin Pract Oncol 3(5): 269-280
    • (2006) Nat Clin Pract Oncol , vol.3 , Issue.5 , pp. 269-280
    • Nahta, R.1    Yu, D.2    Hung, M.C.3    Hortobagyi, G.N.4    Esteva, F.J.5
  • 36
    • 28244432561 scopus 로고    scopus 로고
    • Insulin-like growth factor-i receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells
    • Nahta R, Yuan LX, Zhang B, Kobayashi R, Esteva FJ (2005) Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res 65(23): 11118-11128
    • (2005) Cancer Res , vol.65 , Issue.23 , pp. 11118-11128
    • Nahta, R.1    Yuan, L.X.2    Zhang, B.3    Kobayashi, R.4    Esteva, F.J.5
  • 42
    • 84883359410 scopus 로고    scopus 로고
    • Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: A randomized phase II cardiac safety study (TRYPHAENA)
    • Schneeweiss A, Chia S, Hickish T, Harvey V, Eniu A, Hegg R, Tausch C, Seo JH, Tsai YF, Ratnayake J, McNally V, Ross G, Cortes J (2013) Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol 24(9): 2278-2284
    • (2013) Ann Oncol , vol.24 , Issue.9 , pp. 2278-2284
    • Schneeweiss, A.1    Chia, S.2    Hickish, T.3    Harvey, V.4    Eniu, A.5    Hegg, R.6    Tausch, C.7    Seo, J.H.8    Tsai, Y.F.9    Ratnayake, J.10    McNally, V.11    Ross, G.12    Cortes, J.13
  • 44
    • 37049183697 scopus 로고
    • Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene
    • Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235(4785): 177-182
    • (1987) Science , vol.235 , Issue.4785 , pp. 177-182
    • Slamon, D.J.1    Clark, G.M.2    Wong, S.G.3    Levin, W.J.4    Ullrich, A.5    McGuire, W.L.6
  • 46
    • 79955570584 scopus 로고    scopus 로고
    • Anti-ErbB-2 mAb therapy requires type i and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy
    • Stagg J, Loi S, Divisekera U, Ngiow SF, Duret H, Yagita H, Teng MW, Smyth MJ (2011) Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy. Proc Natl Acad Sci USA 108(17): 7142-7147
    • (2011) Proc Natl Acad Sci USA , vol.108 , Issue.17 , pp. 7142-7147
    • Stagg, J.1    Loi, S.2    Divisekera, U.3    Ngiow, S.F.4    Duret, H.5    Yagita, H.6    Teng, M.W.7    Smyth, M.J.8
  • 47
    • 84877028141 scopus 로고    scopus 로고
    • TCGA-Network (2012) Comprehensive molecular portraits of human breast tumours
    • TCGA-Network (2012) Comprehensive molecular portraits of human breast tumours. Nature 490(7418): 61-70
    • Nature , vol.490 , Issue.7418 , pp. 61-70


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.